Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL1113 in Essential Hypertension and Type II Diabetes Mellitus
NCT07552389Phase 3Recruiting
- Sponsor
- Hanlim Pharm
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanlim Pharm. Primary endpoints: Mean Seated Systolic Blood Pressure at 12 weeks and Glycated Hemoglobin at 12 weeks. Started Dec 2025; status: recruiting.
02
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07552389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552389.